NZ702721A - Vaccination with interleukin-4 antagonists - Google Patents
Vaccination with interleukin-4 antagonistsInfo
- Publication number
- NZ702721A NZ702721A NZ702721A NZ70272113A NZ702721A NZ 702721 A NZ702721 A NZ 702721A NZ 702721 A NZ702721 A NZ 702721A NZ 70272113 A NZ70272113 A NZ 70272113A NZ 702721 A NZ702721 A NZ 702721A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antigen
- interleukin
- subject
- dose
- compositions
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000004388 Interleukin-4 Human genes 0.000 title 1
- 108090000978 Interleukin-4 Proteins 0.000 title 1
- 229940028885 interleukin-4 Drugs 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 229940123418 Interleukin 4 receptor antagonist Drugs 0.000 abstract 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 abstract 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000037452 priming Effects 0.000 abstract 2
- 101710177291 Gag polyprotein Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 102100034353 Integrase Human genes 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 108010078428 env Gene Products Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 108010089520 pol Gene Products Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902345A AU2012902345A0 (en) | 2012-06-05 | Vaccination with Interleukin-4 Antagonists | |
| PCT/AU2013/000589 WO2013181696A1 (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ702721A true NZ702721A (en) | 2016-11-25 |
Family
ID=49711200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702721A NZ702721A (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150150963A1 (enExample) |
| EP (2) | EP3530283A1 (enExample) |
| JP (1) | JP2015520175A (enExample) |
| KR (1) | KR20150021088A (enExample) |
| CN (1) | CN104717971A (enExample) |
| AU (1) | AU2013271338B2 (enExample) |
| BR (1) | BR112014030436A2 (enExample) |
| CA (1) | CA2875683A1 (enExample) |
| HK (1) | HK1203358A1 (enExample) |
| IL (1) | IL236092A0 (enExample) |
| IN (1) | IN2014DN10408A (enExample) |
| NZ (1) | NZ702721A (enExample) |
| SG (1) | SG11201408101TA (enExample) |
| WO (1) | WO2013181696A1 (enExample) |
| ZA (1) | ZA201409076B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3416685B1 (en) | 2016-02-19 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist |
| CN113527485B (zh) | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| JP3282188B2 (ja) | 1991-06-27 | 2002-05-13 | 日本電気株式会社 | 半導体メモリ装置 |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU691175B2 (en) | 1993-03-31 | 1998-05-14 | Nippon Zeon Co., Ltd. | Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| WO1995019799A1 (en) | 1994-01-21 | 1995-07-27 | Agracetus, Inc. | Gas driven gene delivery instrument |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| US6265387B1 (en) | 1995-10-11 | 2001-07-24 | Mirus, Inc. | Process of delivering naked DNA into a hepatocyte via bile duct |
| US6458560B1 (en) | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| WO1999032647A1 (en) | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
| US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US6972013B1 (en) | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US7608273B2 (en) | 1998-08-12 | 2009-10-27 | University Of Western Ontario | Recombinant lentivirus encoding modified GP 120 signal sequences |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
| ATE368122T1 (de) | 1999-04-29 | 2007-08-15 | Cell Genesys Inc | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| AU2001257611A1 (en) | 2000-04-28 | 2001-11-12 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| UA82479C2 (uk) | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| WO2004028563A1 (en) | 2002-09-27 | 2004-04-08 | Genexine Inc. | A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus |
| WO2007121194A1 (en) * | 2006-04-10 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US8048404B1 (en) | 2005-01-04 | 2011-11-01 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles for protein drug delivery |
| US7541046B1 (en) | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US8124398B2 (en) | 2005-04-24 | 2012-02-28 | Sanofi Pasteur Biologics Co. | Recombinant flavivirus vaccines |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| AU2007204879A1 (en) * | 2006-01-11 | 2007-07-19 | Aerovance, Inc. | Methods and compositions for treating asthma in human and non human primates |
| US20090068195A1 (en) * | 2007-04-23 | 2009-03-12 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| EP2414520A2 (en) * | 2009-03-31 | 2012-02-08 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
| AU2010269120B2 (en) * | 2009-07-06 | 2015-09-24 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
-
2013
- 2013-06-05 HK HK15103819.6A patent/HK1203358A1/xx unknown
- 2013-06-05 SG SG11201408101TA patent/SG11201408101TA/en unknown
- 2013-06-05 EP EP19150395.2A patent/EP3530283A1/en not_active Withdrawn
- 2013-06-05 CA CA2875683A patent/CA2875683A1/en not_active Abandoned
- 2013-06-05 AU AU2013271338A patent/AU2013271338B2/en not_active Ceased
- 2013-06-05 EP EP13800233.2A patent/EP2854837A4/en not_active Withdrawn
- 2013-06-05 US US14/405,704 patent/US20150150963A1/en not_active Abandoned
- 2013-06-05 NZ NZ702721A patent/NZ702721A/en not_active IP Right Cessation
- 2013-06-05 IN IN10408DEN2014 patent/IN2014DN10408A/en unknown
- 2013-06-05 CN CN201380040156.6A patent/CN104717971A/zh active Pending
- 2013-06-05 JP JP2015515352A patent/JP2015520175A/ja active Pending
- 2013-06-05 KR KR20147037109A patent/KR20150021088A/ko not_active Withdrawn
- 2013-06-05 WO PCT/AU2013/000589 patent/WO2013181696A1/en not_active Ceased
- 2013-06-05 BR BR112014030436A patent/BR112014030436A2/pt not_active IP Right Cessation
-
2014
- 2014-12-04 IL IL236092A patent/IL236092A0/en unknown
- 2014-12-10 ZA ZA2014/09076A patent/ZA201409076B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150150963A1 (en) | 2015-06-04 |
| EP3530283A1 (en) | 2019-08-28 |
| AU2013271338A1 (en) | 2015-01-15 |
| CN104717971A (zh) | 2015-06-17 |
| AU2013271338B2 (en) | 2018-05-24 |
| IL236092A0 (en) | 2015-01-29 |
| WO2013181696A1 (en) | 2013-12-12 |
| EP2854837A1 (en) | 2015-04-08 |
| IN2014DN10408A (enExample) | 2015-08-14 |
| JP2015520175A (ja) | 2015-07-16 |
| ZA201409076B (en) | 2017-06-28 |
| CA2875683A1 (en) | 2013-12-12 |
| HK1203358A1 (en) | 2015-10-30 |
| EP2854837A4 (en) | 2016-06-29 |
| KR20150021088A (ko) | 2015-02-27 |
| BR112014030436A2 (pt) | 2017-09-26 |
| SG11201408101TA (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009990A (es) | Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r. | |
| EA201891022A1 (ru) | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела | |
| CY1122754T1 (el) | Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r | |
| PH12019502424A1 (en) | Compositions and methods for immunotherapy | |
| CY1120622T1 (el) | Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii | |
| MX2017008186A (es) | Anticuerpos humanos para la hemaglutinina de influenza. | |
| PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| MX384192B (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| BR112016028816A2 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| EA201291105A1 (ru) | Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора | |
| EA201890782A1 (ru) | Способ перенацеливания t-клеток для лечения инфекции hiv | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| MX387755B (es) | Uso de antígenos mhc de clase ii liberados por un replicón vlp en lnmunoterapia de cáncer. | |
| MX346475B (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| BR112017003332A2 (pt) | uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica | |
| MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
| AU2013235442A8 (en) | Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate | |
| HK1203358A1 (en) | Vaccination with interleukin-4 antagonists | |
| MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. | |
| MX2015015918A (es) | Una cepa de mycobacterium bovis bcg recombinante carente del gen bcg1416c, con capacidad de proteccion mejorada contra tuberculosis como candidato a vacuna contra esta enfermedad. | |
| MX2015011485A (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2018 BY SPRUSON + FERGUSON Effective date: 20170512 |
|
| LAPS | Patent lapsed |